272 related articles for article (PubMed ID: 12715624)
1. L-carnitine use in dialysis patients: is national coverage for supplementation justified? What were CMS regulators thinking--or were they?
Steinman TI; Nissenson AR; Glassock RJ; Dickmeyer J; Mattern WD; Parker TF; Hull AR
Nephrol News Issues; 2003 Apr; 17(5):28-30, 32-4, 36 passim. PubMed ID: 12715624
[TBL] [Abstract][Full Text] [Related]
2. L-carnitine supplementation in dialysis patients: does the evidence justify its use?
Steinman TI
Semin Dial; 2005; 18(1):1-2. PubMed ID: 15663752
[TBL] [Abstract][Full Text] [Related]
3. Debate forum: levocarnitine therapy is rational and justified in selected dialysis patients.
Schreiber BD
Blood Purif; 2006; 24(1):128-39. PubMed ID: 16361853
[TBL] [Abstract][Full Text] [Related]
4. CMS national coverage decision for L-carnitine injection--a reasonable process.
Schreiber B
Nephrol News Issues; 2003 Apr; 17(5):40-3, 46. PubMed ID: 12715625
[No Abstract] [Full Text] [Related]
5. L-carnitine supplementation in the dialysis population: are Australian patients missing out?
Reuter SE; Faull RJ; Evans AM
Nephrology (Carlton); 2008 Feb; 13(1):3-16. PubMed ID: 18199095
[TBL] [Abstract][Full Text] [Related]
6. Dialysis-related carnitine disorder.
Hedayati SS
Semin Dial; 2006; 19(4):323-8. PubMed ID: 16893411
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the effect of intravenous l-carnitine on quality of life in chronic hemodialysis patients.
Semeniuk J; Shalansky KF; Taylor N; Jastrzebski J; Cameron EC
Clin Nephrol; 2000 Dec; 54(6):470-7. PubMed ID: 11140808
[TBL] [Abstract][Full Text] [Related]
8. [Tuberculosis in compromised hosts].
Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
[TBL] [Abstract][Full Text] [Related]
9. Effect of dialysate composition on the lipid response to L-carnitine supplementation.
Zilleruelo G; Novak M; Hsia SL; Goldberg R; Abitbol C; Monkus E; Strauss J
Kidney Int Suppl; 1989 Nov; 27():S259-63. PubMed ID: 2699997
[TBL] [Abstract][Full Text] [Related]
10. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
11. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
12. Linking Centers for Medicare & Medicaid Services data with prospective DCOR trial data: methods and data comparison results.
St Peter WL; Liu J; Weinhandl ED; Fan Q
Hemodial Int; 2008 Oct; 12(4):480-91. PubMed ID: 19090871
[TBL] [Abstract][Full Text] [Related]
13. Should the medicare ESRD program pay for daily dialysis? An ethical analysis.
Anantharaman P; Moss AH
Adv Chronic Kidney Dis; 2007 Jul; 14(3):290-6. PubMed ID: 17603984
[TBL] [Abstract][Full Text] [Related]
14. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
[TBL] [Abstract][Full Text] [Related]
15. Disability benefit coverage and program interactions in the working-age population.
Rupp K; Davies PS; Strand A
Soc Secur Bull; 2008; 68(1):1-30. PubMed ID: 18837269
[TBL] [Abstract][Full Text] [Related]
16. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
17. The effects of L-carnitine therapy on respiratory function tests in chronic hemodialysis patients.
Bavbek N; Akay H; Uz B; Uz E; Turgut F; Kanbay M; Senes M; Akcay A; Duranay M
Ren Fail; 2010 Jan; 32(2):157-61. PubMed ID: 20199175
[TBL] [Abstract][Full Text] [Related]
18. Carnitine replacement in end-stage renal disease and hemodialysis.
Calvani M; Benatti P; Mancinelli A; D'Iddio S; Giordano V; Koverech A; Amato A; Brass EP
Ann N Y Acad Sci; 2004 Nov; 1033():52-66. PubMed ID: 15591003
[TBL] [Abstract][Full Text] [Related]
19. The direction of end-stage renal disease reimbursement in the United States.
Lockridge RS
Semin Dial; 2004; 17(2):125-30. PubMed ID: 15043614
[TBL] [Abstract][Full Text] [Related]
20. Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed?
Berns JS
Semin Dial; 2005; 18(1):22-9. PubMed ID: 15663760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
